Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Phase 2 Terminated
19 enrolled 10 charts
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
Phase 2 Terminated
3 enrolled 12 charts
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Phase 2 Terminated
18 enrolled
Pembro+Chemo in Brain Mets
Phase 2 Terminated
3 enrolled 7 charts
ACT-FAST
Phase 2 Terminated
2 enrolled
RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases
Phase 2 Terminated
14 enrolled
STIR
Phase 2 Terminated
15 enrolled 11 charts
NORTH
Phase 2 Terminated
25 enrolled
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Phase 2 Terminated
90 enrolled 13 charts
CA209-322
Phase 2 Terminated
7 enrolled
UVA-Gen001
Phase 2 Terminated
4 enrolled 16 charts
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
Phase 2 Terminated
3 enrolled 13 charts
CLQ
Phase 2 Terminated
73 enrolled
RadioCoBRIM
Phase 2 Terminated
20 enrolled
Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors
Phase 2 Terminated
40 enrolled 8 charts
POLARIS
Phase 2 Terminated
13 enrolled 55 charts
Seizure Prophylaxis in Patients With Glioma or Brain Metastasis
Phase 2 Terminated
4 enrolled 8 charts
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Phase 2 Terminated
19 enrolled 15 charts
KING
Phase 2 Terminated
76 enrolled 16 charts
Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma
Phase 2 Terminated
5 enrolled
Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation
Phase 2 Terminated
116 enrolled 12 charts
A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)
Phase 2 Terminated
13 enrolled 23 charts
Brigatinib Before Brain Irradiation Trial (B3i Trial)
Phase 2 Terminated
1 enrolled 6 charts
Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children
Phase 2 Terminated
4 enrolled 6 charts
Neoadjuvant Immunotherapy in Brain Metastases
Phase 2 Terminated
1 enrolled 7 charts
Sunitinib in Sarcomas of the Central Nervous System
Phase 2 Terminated
5 enrolled 14 charts
High Dose Chemotherapy With Amifostine and Autologous Stem Cell Transplantation for High Risk Relapsed Pediatric Solid Tumors and Brain Tumors
Phase 2 Terminated
2 enrolled 4 charts
Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
Phase 2 Terminated
6 enrolled 3 charts
NANOSTEREO
Phase 2 Terminated
1 enrolled
Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
Phase 2 Terminated
4 enrolled 10 charts
Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases
Phase 2 Terminated
5 enrolled 18 charts
Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
Phase 2 Terminated
1 enrolled 5 charts
HX4 SD
Phase 2 Terminated
1 enrolled
Stereotactic Radiosurgery After Surgery in Treating Patients With Brain Metastases
Phase 2 Terminated
1 enrolled 6 charts
CEST- Glucose Enhanced MRI for Metastatic Brain Tumours
Phase 2 Terminated
3 enrolled
GRABM-L
Phase 2 Terminated
16 enrolled 7 charts
FMISOPETSCS
Phase 2 Terminated
6 enrolled
Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
Phase 2 Terminated
6 enrolled 9 charts
Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme
Phase 2 Terminated
8 enrolled 7 charts
Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas
Phase 2 Terminated
10 enrolled
CaBaMet
Phase 2 Terminated
8 enrolled
Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients
Phase 2 Terminated
1 enrolled 9 charts
NRR
Phase 2 Terminated
10 enrolled 14 charts
Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme
Phase 2 Terminated
30 enrolled 10 charts
STOP
Phase 2 Terminated
6 enrolled 9 charts
Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma
Phase 2 Terminated
38 enrolled 8 charts
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
Phase 2 Terminated
47 enrolled 9 charts
O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy
Phase 2 Terminated
12 enrolled 10 charts
Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas
Phase 2 Terminated
10 enrolled 6 charts
Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)
Phase 2 Terminated
30 enrolled